Amicus Therapeutics Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -233.29 M-202.49 M-166.57 M-69.09 M-33.89 M33.15 M 33.15 M Mittelzufluss aus Investitionstätigkeit -13.58 M78.76 M92.32 M98.06 M-560 K-46.43 M -46.43 M Zahlungsströme aus der Finanzierungstätigkeit 262.86 M212.07 M-7.46 M61.68 M5.12 M610 K 610 K Freier Cashflow -236.52 M-206.38 M-170.34 M-76.53 M-37.44 M29.85 M 29.85 M

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

FOLD

Financials

Amicus Therapeutics Inc

Nachrichten

Amicus Therapeutics-Aktie markiert 52-Wochen-Hoch bei 14,46 USD

Aktie von Amicus Therapeutics erreicht 52-Wochen-Hoch bei $14,44

Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating

Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating

BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?

Amicus Therapeutics erreicht 52-Wochen-Hoch vor BioMarin-Übernahme

Amicus Therapeutics erreicht 52-Wochen-Hoch bei 14,38 USD

Amicus Therapeutics stock hits 52-week high at 14.38 USD

BofA senkt Kursziel für BioMarin wegen Voxzogo-Ausblick auf 85 US-Dollar

Viking Therapeutics Stock Gets RS Rating Upgrade